News
-
-
-
COMMUNIQUÉ DE PRESSE
Somagenetix AG secures CHF 10 million in Series A financing to advance lentiviral gene therapy for Chronic Granulomatous Disease (CGD)
Somagenetix AG secures CHF 10 million in Series A financing to advance lentiviral gene therapy for Chronic Granulomatous Disease (CGD). Vi Partners leads the financing round alongside existing investors Schroders Capital, Zürcher Kantonalbank, and Verve Ventures